News
XRTX
0.4295
+1.30%
0.0055
XORTX Therapeutics Secures Exchange Approvals for 1-for-5 Share Consolidation Effective April 6
TipRanks · 3d ago
Xortx Therapeutics to effect 5-for-1 share consolidation on April 6
TipRanks · 3d ago
XORTX Therapeutics Announces 1-For-5 Share Consolidation, Effective April 6, 2026
Benzinga · 3d ago
XORTX THERAPEUTICS INC - TO CONSOLIDATE SHARES 1-FOR-5 EFFECTIVE APRIL 6, 2026
Reuters · 3d ago
XORTX to consolidate shares 1-for-5 effective April 6
Reuters · 3d ago
XORTX Confirms Effective Date of Share Consolidation
Barchart · 4d ago
Weekly Report: what happened at XRTX last week (0323-0327)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 03/27 17:05
XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting
TipRanks · 03/26 22:39
XORTX Therapeutics held its annual and special meeting of shareholders; 2.4 million shares were represented, about 35% of outstanding shares
Reuters · 03/26 22:02
XORTX Delays Effective Date of One-for-Five Share Consolidation
TipRanks · 03/26 21:16
XORTX Therapeutics Delays 1-for-5 Share Consolidation To April 6, Pending Approvals
Benzinga · 03/26 20:42
XORTX Therapeutics delays 1-for-5 share consolidation effective date to April 6, 2026; consolidation shifts from March 27, 2026
Reuters · 03/26 20:37
XORTX THERAPEUTICS INC - DELAYS SHARE CONSOLIDATION TO APRIL 6, 2026
Reuters · 03/26 20:33
XORTX Announces Results of Annual and Special Meeting of Shareholders
Barchart · 03/26 17:00
XORTX Announces Change of Effective Date of Share Consolidation
Barchart · 03/26 15:32
XORTX Consolidates Shares in Bid to Maintain Nasdaq Listing
TipRanks · 03/26 02:17
XORTX THERAPEUTICS INC - APPROVES SHARE CONSOLIDATION AT 1-FOR-5 RATIO EFFECTIVE MARCH 27, 2025
Reuters · 03/25 22:15
XORTX Therapeutics approves 1-for-5 share consolidation; post-consolidation trading starts March 27, 2026
Reuters · 03/25 22:15
XORTX Announces Share Consolidation
Barchart · 03/25 17:15
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.